| 生物活性 |
10-Hydroxy-2-decenoic acid (10-HDA) is an orally active unsaturated medium-chain fatty acid with multiple physiological activities that induces ROS-mediated apoptosis in A549 cells, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells, alleviates non-alcoholic fatty liver disease (NAFLD) by activating the AMPK-α signaling pathway, prevents bone loss by inhibiting the NF-κB signaling pathway downstream of FFAR4, acts as an antibiotic against various bacteria and fungi (such as Neurospora sitophila, molds, and Staphylococcus aureus), exerts longevity-promoting effects in Caenorhabditis elegans, and prevents osteoarthritis by targeting aspartyl β-hydroxylase and inhibiting chondrocyte senescence. |
体外研究 (In Vitro) |
10-Hydroxy-2-decenoic acid (0-40 nM,0-6 天) 可促进原代软骨细胞和人 C28/I2 软骨细胞的增殖和合成代谢,同时抑制其凋亡和分解代谢。
10-Hydroxy-2-decenoic acid (0-10 nM,7 天) 可增强人骨关节炎 (OA) 软骨外植体中的软骨细胞合成代谢,并抑制其分解代谢。
10-Hydroxy-2-decenoic acid (0-200 μM, 1-48 小时) 可与 ASPH 结合,并调节 C28/I2 和 HEK-293T 细胞中依赖于 ASPH 的 Asp-Arg-Hydrox 结构域的软骨细胞代谢。
10-Hydroxy-2-decenoic acid (0-10 nM,48 小时) 可降低 C28/I2 细胞中衰老相关的 β-半乳糖苷酶 (SA-β-gal) 以及细胞衰老标志基因 p16 和 p21 的 mRNA 水平。
10-Hydroxy-2-decenoic acid (0-10 nM,48 小时) 通过调节 ASPH-KO C28/I2 细胞中的 ASPH/ERK/p53/p21 和 ASPH/GSK3β/p16 信号通路来抑制软骨细胞衰老。
10-Hydroxy-2-decenoic acid (2 mg/mL) 在低 pH 值条件下对 6C3HED 淋巴肉瘤细胞具有抗肿瘤活性。
10-Hydroxy-2-decenoic acid (50-150 μM) 通过激活 AML12 细胞中的 AMPK-α 来阻止 FFA 诱导的脂质积累和细胞凋亡。
10-Hydroxy-2-decenoic acid (0.07-1.13 mg/mL,24 小时) 通过破坏胞外多糖 (EPS) 结构来降低生物膜的生物量和细胞活力,并抑制金黄色葡萄球菌溶血素的产生。
10-Hydroxy-2-decenoic acid (20-500 μM,11 天) 可降低 HUVECs 细胞和成纤维细胞中 VEGF 诱导的血管形成。
10-Hydroxy-2-decenoic acid (20-500 μM,3 天) 在 500 μM 浓度下可抑制 VEGF 诱导的 HUVEC 细胞增殖,但在 20-100 μM 浓度下不抑制 HUVEC 细胞增殖。
10-Hydroxy-2-decenoic acid (500 μM,24 小时) 可抑制 HUVEC 细胞迁移。
10-Hydroxy-2-decenoic acid (1-100 μM,3-36 h) 抑制 A549、NCI-H460 和 NCI-H23 细胞的生长,IC50 分别为 22.68、44.03 和 44.79 μM,对 IMR90、L-02 和 GES-1 细胞有较弱的细胞毒性。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调控 A549 细胞中的 MAPK、NF-κB 和 STAT3 信号通路,增加 ROS 水平,诱导细胞凋亡。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调控 A549 细胞中细胞周期相关蛋白的表达,诱导细胞周期阻滞。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调节 A549 细胞中的 TGF-β1 信号通路来抑制细胞迁移。
10-Hydroxy-2-decenoic acid (10-100 μM,50 天) 通过独立于 IIS-DAF-16 通路的机制延长 daf-16 (mu86) 突变体和野生型秀丽隐杆线虫的平均和最大寿命。
10-Hydroxy-2-decenoic acid (0.00004-20 mM) 可激活 FFAR4,EC50 为 1.025 mM。
10-Hydroxy-2-decenoic acid (12.5-50 ng/mL,3 天) 通过 FFAR4 受体抑制 NF-κB 信号通路,从而抑制原发性骨髓细胞破骨细胞生成。
RT-PCR
| Cell Line: |
Primary chondrocytes, Human C28/I2 chondrocytes |
| Concentration: |
0 nM, 2 nM, 5 nM, 10 nM, 20 nM, 40 nM |
| Incubation Time: |
0, 2, 4, 6 days |
| Result: |
Promoted the mRNA levels of CDK1, CDK2, CDK4, CDK6, cyclin A1, cyclin B1, cyclin D1, cyclin E1, proliferating cell nuclear antigen (PCNA), SRY-box transcription factor 9 (SOX9), COL2 and aggrecan (ACAN).
Inhibited the mRNA levels of COL1A1, COL1A2, COL3A1, α-SMA, FMOD, and FNDC1.
Increased the mRNA levels of CDK1, CDK2, CDK4, CDK6, cyclinA1, cyclinB1, cyclinD1, cyclinE1, and PCNA, SOX9, COL2, and ACAN, while inhibiting the expression of MMP13 and IL6 in the presence of IL-1β (10 ng/mL, 48 h).
|
Western Blot Analysis
| Cell Line: |
Human OA cartilage explants |
| Concentration: |
0 nM, 5 nM, 10 nM |
| Incubation Time: |
7 days |
| Result: |
Upregulated COL2 and ACAN protein levels and downregulated MMP13 protein levels.
|
RT-PCR
| Cell Line: |
C28/I2 cells |
| Concentration: |
0 nM, 5 nM, 10 nM |
| Incubation Time: |
7 days |
| Result: |
Reduced ASPH and COL2 protein levels and increased MMP13 protein levels in knocked down the ASPH expression.
|
Cell Migration Assay
| Cell Line: |
HUVECs |
| Concentration: |
500 µM |
| Incubation Time: |
24 h |
| Result: |
Inhibited cell migration. |
Apoptosis Analysis
| Cell Line: |
A549 human lung cancer cells |
| Concentration: |
30 μM |
| Incubation Time: |
3, 24 h |
| Result: |
Increased numbers of early and late apoptotic cells, loss of mitochondrial membrane potential (MMP), increased proportion of depolarized cells.
Downregulated Bcl-2, and upregulated BAX, cyto-c, caspase-3, and PARP.
Upregulated p-p38, p-JNK, and I-κB and downregulated p-ERK, p-STAT3, and NF-κB.
|
Cell Cycle Analysis
| Cell Line: |
A549 human lung cancer cells |
| Concentration: |
30 μM |
| Incubation Time: |
3, 24 h |
| Result: |
Increased the percentage of cells in the G0/G1 phase from 62.97% to 80.54%, downregulated AKT, CDK2/4/6, and cyclin D1/E, and upregulated p21 and p27. |
Cell Migration Assay
| Cell Line: |
A549 human lung cancer cells |
| Concentration: |
30 μM |
| Incubation Time: |
3, 24 h |
| Result: |
Inhibited cell migration, reduced the expression levels of TGF-β1, SNAI1, GSK-3β, N-cadherin and vimentin, and increased the expression level of E-cadherin. |
Western Blot Analysis
| Cell Line: |
Primary bone marrow cells |
| Concentration: |
12.5-50 ng/mL |
| Incubation Time: |
3 days |
| Result: |
Reduced protein levels of CtsK, TRAP, V-ATPase D2, and MMP9.
Diminished RANKL-induced phosphorylation and the degradation of IκBα.
|
RT-PCR
| Cell Line: |
Primary bone marrow cells |
| Concentration: |
12.5-50 ng/mL |
| Incubation Time: |
3 days |
| Result: |
Had no influence on the expression of Tnfrsf11a (encodes RANK), Csf1r (encodes M-CSFR), Fos, and Mitf.
Decreased osteoclastogenesis Nfatc1 and its downstream elements, without affecting the expression of Irf8 and Mafb.
|
|
体内研究 (In Vivo) |
10-Hydroxy-2-decenoic acid (10 mg/kg,关节腔内注射,每周两次,6 周;100 mg/kg,口服,每周三次,7 周) 在内侧半月板不稳定 (DMM) 小鼠中可促进软骨合成代谢,抑制软骨退化,并缓解手术诱发的膝关节疼痛。
10-Hydroxy-2-decenoic acid (10 mg/kg,关节腔内注射,每周两次,8 周;100 mg/kg,口服,每周三次,8 周) 可缓解自然衰老小鼠的软骨细胞衰老和软骨退化。
10-Hydroxy-2-decenoic acid (0.5-2 mg/mL,皮下注射,一次) 完全抑制了 AKR 小鼠和腹水瘤小鼠的肿瘤发展。
10-Hydroxy-2-decenoic acid (10-50 mg/kg,口服,每日一次,4 周) 对 Methionine (MS-X03991)-Choline (MS-A15337) deficient (MCD) 饮食诱导的 NAFLD 小鼠具有强大的保护作用,可防止脂质积聚和肝损伤,并防止细胞凋亡。
10-Hydroxy-2-decenoic acid (基础日粮中含有1-5 g/kg,口服,21天) 通过抗炎、抗氧化和肠道菌群调节活性减轻了 LPS (MS-X54539) 诱导的肠粘膜损伤鸡模型中的肠道损伤和生长性能损失。
10-Hydroxy-2-decenoic acid (40 mg/kg,口服,每日一次,4 周) 可抑制卵巢切除术 (OVX) 小鼠的破骨细胞骨吸收,而不会影响 OVX 小鼠的骨形成。
| Animal Model: |
DMM mouse (8-week-old male C57BL/6 J) model |
| Dosage: |
10 mg / kg; 100 mg/kg |
| Administration: |
IA injection, twice a week for 6 weeks; p.o., three times a week for 7 weeks |
| Result: |
Increased the number of chondrocytes, improved knee cartilage erosion and superficial cartilage loss, inhibited cartilage degradation, increased the protein and mRNA levels of Col2 and Acan, and reduced the protein and mRNA levels of Mmp13.
Reduced pain-related behaviors associated with OA and DMM surgery.
Was not associated with any significant toxicity in oral administration group.
Inhibited the OA-induced down-regulation of ASPH expression.
Reduced p16 and p21 protein levels.
|
| Animal Model: |
Naturally aged (18 months old, male) C57BL/6 J mice model |
| Dosage: |
10 mg/kg; 100 mg/kg |
| Administration: |
IA injection, twice a week for 8 weeks; p.o., three times a week for 8 weeks |
| Result: |
Reduced knee joint diameter, prevented joint swelling, partially alleviated aging-related cartilage degeneration, and improved OARSI scores.
Reduced p16, p21, and Mmp13 protein levels and increased Col2 protein and ASPH expression.
|
| Animal Model: |
AKR (2-5 million tumor cells) mice (female mice, 5-6 weeks) model |
| Dosage: |
0.5 mg/mL, 1 mg/mL, 1.5 mg/mL, 2.0 mg/mL, 0.2 mL/mouse |
| Administration: |
s.c., once |
| Result: |
Had completely prevented the development of transplantable leukemia at 1.5 mg/mL.
|
| Animal Model: |
Ascitic tumor (the 6CSHED lymphosarcoma, the TAS mammary carcinoma, and the Ehrlich carcinoma, 5-8 million tumor cells) connaught mice (Male mice, 20-22 g) model |
| Dosage: |
0.6 mg/mL, 1 mg/mL, 2.0 mg/mL |
| Administration: |
s.c., once |
| Result: |
Showed slight activity at a level of 0.6 mg/mL, while conferred complete protection at 1.0 mg/mL.
|
| Animal Model: |
MCD diet (5 weeks)-induced NAFLD in mice (Male C57BL/6, 6 weeks of age, weighing 20∼25 g) model |
| Dosage: |
10 mg/kg; 50 mg/kg |
| Administration: |
p.o., once a day, 4 weeks |
| Result: |
Inhibited weight loss, reduced fat droplets, and lowered liver TG by 32% and 60%, respectively.
Reduced hepatocyte vacuoles and ballooning, and attenuated ALT and AST levels.
Reduced TUNEL cell area, reduced BAX expression and increased BCL2 expression.
Was involved in hepatic inflammatory recruitment mainly by regulating the infiltration of macrophages and neutrophils.
Suppressed hepatic lipid accumulation by regulation lipogenesis and fatty acid β-oxidation.
|
| Animal Model: |
LPS-induced (0.5 mg/kg, i.p.) intestinal mucosal injury chickens (one-day-old male) model |
| Dosage: |
0.1% group, basal diet containing 1 g/kg; 0.5% group, basal diet containing 5 g/kg
|
| Administration: |
p.o., 21 days |
| Result: |
Reduced feed-to-weight ratios in chickens, but had no significant effect on ADFI and ADG.
Alleviated bleeding in the duodenum, jejunum, and ileum, reduced epithelial villous damage in the jejunum and ileum, reduced serum DAO levels and CD in the jejunum, and increased VCR in the jejunum and ileum.
Reduced serum TNF-α, IL-1β, and IL-6 levels, increased serum IgA and IgG concentrations, had no significant effect on TNF-α and IL-1β levels in the 0.5% group, and increased CAT and GSH-px activities in the 0.5% group.
Downregulated the mRNA expression levels of TLR4, NF-κB, IL-1β, IL-6, TNF-α, and Caspase-3, increased Bcl2 expression, and had no significant effect on the mRNA expression levels of TLR4, IL-1β, IL-6, Bax, and Caspase-3 in the 0.5% group, increased expression levels of CAT, SOD2, ZO-1, and OCLN.
|
| Animal Model: |
OVX mice (Eight-week–old female C57BL6/J) model |
| Dosage: |
40 mg/kg |
| Administration: |
p.o., once a day, 4 weeks |
| Result: |
Inhibited the serum levels of C-terminal telopeptide of type I collagen (CTX-I) that contributes to osteoclast activity, without altering the serum levels of N-terminal propeptide of type I collagen (PINP).
|
|
| 性状 |
固体 |
| 颜色 |
White to off-white |